The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges
Open accessAbstract
Islet transplantation is a well-established therapeutic treatment for a subset of patients with complicated type I diabetes mellitus. Prior to the Edmonton Protocol, only 9% of the 267 islet transplant recipients since 1999 were insulin independent for >1 year. In 2000, the Edmonton group reported the achievement of insulin independence in seven consecutive patients, which in a collaborative team effort propagated expansion of clinical islet transplantation centers worldwide in an effort to ameliorate the consequences of this disease. To date, clinical islet transplantation has established improved success with insulin independence rates up to 5 years post-transplant with minimal complications. In spite of marked clinical success, donor availability and selection, engraftment, and side effects of immunosuppression remain as existing obstacles to be addressed to further improve this therapy. Clinical trials to improve engraftment, the availability of insulin-producing cell sources, as well as alternative transplant sites are currently under investigation to expand treatment. With ongoing experimental and clinical studies, islet transplantation continues to be an exciting and attractive therapy to treat type I diabetes mellitus with the prospect of shifting from a treatment for some to a cure for all.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 1×
“83 These studies were fundamental in the establishment of a robust methodology for consistent, large scale production of this cellular source by Schulz et al 84 which will undoubtedly serve as a platform to circumvent cadaveric donor shortages by providing a potentially unlimited supply of…”
Five-Year Follow-Up After Clinical Islet Transplantation
Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R. T., & Shapiro, A. M. J. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2060 · Cited by 1,641
Self-citationImprovement in outcomes of clinical islet transplantation: 1999–2010
Barton, F. B., Rickels, M. R., Alejandro, R., Hering, B. J., Wease, S., Naziruddin, B., Oberholzer, J., Odorico, J. S., Garfinkel, M. R., Levy, M., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0063 · Cited by 725
Self-citationVoltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simões, B. P., et al. (2007) · JAMA · doi:10.1001/jama.297.14.1568 · Cited by 573
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411 · cited 1×
“However, when compared to the standard insulin pump control group, no change in glycosylated hemoglobin (HbA 1c ) was observed.(16) On the contrary, islet transplantation has the ability to correct HbA 1c to levels that can predictably reverse the secondary consequences of diabetes.”
Optimal implantation site for pancreatic islet transplantation
Merani, S., Toso, C., Emamaullee, J., & Shapiro, A. M. J. (2008) · British Journal of Surgery · doi:10.1002/bjs.6391 · Cited by 257 · cited 1×
“Multiple studies report the enormous stress to which the islets are exposed during the first days after transplant.(39,47,48) Multiple factors combine and contribute to apoptosis and cell death, resulting in islet tissue loss of around 60%.”
Self-citationThompson, D. M., Meloche, M., Ao, Z., Paty, B., Keown, P., Shapiro, R. J., Ho, S., Worsley, D., Fung, M., Meneilly, G., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31820437f3 · Cited by 213
Visualization of Early Engraftment in Clinical Islet Transplantation by Positron-Emission Tomography
Eich, T., Eriksson, O., & Lundgren, T. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070201 · Cited by 198 · cited 2×
“68,69 In spite of the advantages associated with PET, long-term utility of this imaging modality is primarily limited to washout of radioactive tracers once islets have made contact with blood in the portal vein.”
Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment
Nilsson, B., Ekdahl, K. N., & Korsgren, O. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834c2393 · Cited by 194
Factors Influencing the Loss of β-Cell Mass in Islet Transplantation
Emamaullee, J. A., & Shapiro, A. M. J. (2007) · Cell Transplantation · doi:10.3727/000000007783464461 · Cited by 172
Self-citation
Cited by
Type-2 diabetes mellitus and cardiovascular disease
Henning, R. J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0045 · Cited by 398
Cryopreservation: An Overview of Principles and Cell-Specific Considerations
Whaley, D., Damyar, K., Witek, R. P., Mendoza, A., Alexander, M., & Lakey, J. R. (2021) · Cell Transplantation · doi:10.1177/0963689721999617 · Cited by 403
Lancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., Hitchcock, J., Mason, C., Montgomery, J., Morris, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 272
Sackett, S. D., Tremmel, D. M., Ma, F., Feeney, A. K., Maguire, R. M., Brown, M. E., Zhou, Y., Li, X., O’Brien, C., Li, L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28857-1 · Cited by 269
Nojehdehi, S., Soudi, S., Hesampour, A., Rasouli, S., Soleimani, M., & Hashemi, S. M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27260 · Cited by 262
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
Ferroptosis-inducing agents compromise in vitro human islet viability and function
Bruni, A., Pepper, A. R., Pawlick, R. L., Gala-Lopez, B., Gamble, A. F., Kin, T., Seeberger, K., Korbutt, G. S., Bornstein, S. R., Linkermann, A., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0506-0 · Cited by 180
Self-citationWeaver, J. D., Headen, D. M., Aquart, J., Johnson, C. T., Shea, L. D., Shirwan, H., & García, A. J. (2017) · Science Advances · doi:10.1126/sciadv.1700184 · Cited by 170
A new era of macrophage-based cell therapy
Na, Y. R., Kim, S. W., & Seok, S. H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01068-z · Cited by 129
Samojlik, M. M., & Stabler, C. L. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.039 · Cited by 38
Metadata
- Authors
- Shapiro, J., Bruni, A., Pepper, A. R., Gala-Lopez, B., & Abualhassan, N. S.
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2014-06
- Volume
- 7
- Pages
- 211
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W2026686604
- Cited by
- 232
- References
- 13
- FWCI
- 27.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.